VEGFA and type 2 diabetes mellitus: found anti-VEGF injections in patients with type 2 diabetes to be independently associated with an increased likelihood (odds ratio 1.8) of syAEs, with the 5‐year cumulative incidence of any syAE being 37.0% in the anti-VEGF group compared to 18.4% in the non-injection group [85].